Tirzepatide for Obesity Treatment and Diabetes Prevention
Autores: Jastreboff AM, le Roux CW, Stefanski A, Aronne LJ, Halpern B, et al.
Revista
N Engl J Med
Año
2025
Citas
200
Type
Clinical Trial
Subject
Human
Condition
Obesity / Type 2 Diabetes
TL;DR
SURMOUNT-1 trial: tirzepatide showed sustained weight loss over 72 weeks and delayed progression to type 2 diabetes in patients with obesity and prediabetes.
Ver Artículo
DOI: 10.1056/NEJMoa2410819
Abstract
Obesity is a chronic disease and causal precursor to myriad other conditions, including type 2 diabetes.. In an earlier analysis of the SURMOUNT-1 trial, tirzepatide was shown to provide substantial and sustained reductions in body weight in persons with obesity over a 72-week period.. Here, we report the 3-year safety outcomes with tirzepatide and its efficacy in reducing weight and delaying.